NCMD Research Seminar Series 14th November 2025

Presenters: Dr Nadia Lipunova, SVP of Real-World Evidence, Holmusk and Dr Kira Griffiths, Lead Research Scientist, Holmusk

Real-world evidence in psychiatry: NeuroBlu Data
• Introduction to NeuroBlu Data (Nadia)
• Latent class trajectory analysis of abnormal movements associated with antipsychotic treatment (Kira)
• Semaglutide and cognition among patients with psychiatric conditions (Nadia)

Dr Nadia Lipunova (SVP of Real-World Evidence, Holmusk)
Nadia is an experienced Real-World Evidence specialist and team leader with over 10 years in the biotechnology and healthcare sectors. Currently serving as Senior Vice President of RWE at Holmusk, she previously led biostatistics and analytics teams at OPEN Health and Sensyne Health, where she focused on extracting actionable insights from complex healthcare datasets.

Having worked across multiple therapeutic areas and international collaborations, including earning a PhD in genetic epidemiology and leading projects with the European Commission and WHO, she brings a unique perspective to transforming real-world data into meaningful evidence that supports clinical decision-making and product development across all stages of the healthcare continuum.

Dr Kira Griffiths (Lead Research Scientist, Holmusk)

Kira is a research scientist focused on translational research in psychiatry with a specialist interest in understanding how to better care for people with severe mental illness, such as psychotic disorders. She has worked at the intersection of academia and industry and is currently a lead within the analytics team at Holmusk, where she focuses on utilising real-world data to generate meaningful evidence to support clinical research and therapeutic development.

She brings perspective from diverse experience with clinical research, multimodal data analysis, and large-scale healthcare datasets, and holds a PhD in Clinical Neuroscience from the Institute of Psychiatry, Psychology & Neuroscience, King's College London.

In this talk, Nadia & Kira will introduce NeuroBlu Data, which comprises electronic health records of >36M individuals in the US with psychiatric and neurological conditions. They will also share examples of two projects that highlight the importance of real-world data in the field of psychiatry. First, Kira will discuss the evidence of routine implementation of the Abnormal Involuntary Movement Scale (AIMS) to monitor trajectories of abnormal movements among patients receiving treatment with antipsychotics.

Secondly, Nadia will present the results of an analysis using causal inference methods that aims to assess the impact of semaglutide on cognition among patients with psychiatric disorders.